image
TransMedics Group, Inc. TMDX
Healthcare - Medical - Devices - NASDAQ - US
Watchlist
$ 129.19
1.17 %
$ 4.37 B
Market Cap
90.98
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one TMDX stock under the worst case scenario is HIDDEN Compared to the current market price of 129 USD, TransMedics Group, Inc. is HIDDEN

TMDX Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one TMDX stock under the base case scenario is HIDDEN Compared to the current market price of 129 USD, TransMedics Group, Inc. is HIDDEN

TMDX Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one TMDX stock under the best case scenario is HIDDEN Compared to the current market price of 129 USD, TransMedics Group, Inc. is HIDDEN

TMDX Intrinsic Value
HIDDEN
SHOW
2. FUNDAMENTAL ANALYSIS

Price Chart TMDX

image
1M -11%
6M 88%
1Y -12%
3Y 287%
5Y 662%
All
$150.0$150.0$140.0$140.0$130.0$130.0$120.0$120.0$110.0$110.0$100.0$100.0$90.0$90.0$80.0$80.0$70.0$70.0$60.0$60.0$50.0$50.015 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 JunJul '25Jul '25
FINANCIALS
442 M REVENUE
82.74%
Growth Rates
1Year 82.74%
3Years 144.36%
5Years 79.64%
7Years 78.37%
10Years 0.00%
37.5 M OPERATING INCOME
230.53%
Growth Rates
1Year 230.53%
3Years 43.44%
5Years 26.71%
7Years 21.17%
10Years 0.00%
35.5 M NET INCOME
241.70%
Growth Rates
1Year 241.70%
3Years 40.98%
5Years 25.04%
7Years 20.57%
10Years 0.00%
48.8 M OPERATING CASH FLOW
474.60%
Growth Rates
1Year 474.60%
3Years 54.54%
5Years 28.56%
7Years 22.39%
10Years 0.00%
-129 M INVESTING CASH FLOW
33.33%
Growth Rates
1Year 33.33%
3Years -75.64%
5Years -16.40%
7Years -29.78%
10Years 0.00%
22.9 M FINANCING CASH FLOW
-94.29%
Growth Rates
1Year -94.29%
3Years 154.17%
5Years -24.42%
7Years 258.59%
10Years 0.00%
144 M REVENUE
18.02%
Growth Rates
1Year 82.74%
3Years 144.36%
5Years 79.64%
7Years 78.37%
10Years 0.00%
27.4 M OPERATING INCOME
217.48%
Growth Rates
1Year 230.53%
3Years 43.44%
5Years 26.71%
7Years 21.17%
10Years 0.00%
25.7 M NET INCOME
274.54%
Growth Rates
1Year 241.70%
3Years 40.98%
5Years 25.04%
7Years 20.57%
10Years 0.00%
-2.86 M OPERATING CASH FLOW
-14.52%
Growth Rates
1Year 474.60%
3Years 54.54%
5Years 28.56%
7Years 22.39%
10Years 0.00%
-27 M INVESTING CASH FLOW
-98.72%
Growth Rates
1Year 33.33%
3Years -75.64%
5Years -16.40%
7Years -29.78%
10Years 0.00%
3.03 M FINANCING CASH FLOW
155.31%
Growth Rates
1Year -94.29%
3Years 154.17%
5Years -24.42%
7Years 258.59%
10Years 0.00%
Balance Sheet TransMedics Group, Inc.
image
Current Assets 497 M
Cash & Short-Term Investments 337 M
Receivables 97.7 M
Other Current Assets 62.8 M
Non-Current Assets 307 M
Long-Term Investments 0
PP&E 292 M
Other Non-Current Assets 14.4 M
41.87 %12.15 %7.82 %36.37 %Total Assets$804.1m
Current Liabilities 59.9 M
Accounts Payable 10.3 M
Short-Term Debt 2.73 M
Other Current Liabilities 46.9 M
Non-Current Liabilities 516 M
Long-Term Debt 516 M
Other Non-Current Liabilities 0
8.15 %89.59 %Total Liabilities$575.5m
EFFICIENCY
Earnings Waterfall TransMedics Group, Inc.
image
Revenue 442 M
Cost Of Revenue 179 M
Gross Profit 262 M
Operating Expenses 225 M
Operating Income 37.5 M
Other Expenses 2.03 M
Net Income 35.5 M
450m450m400m400m350m350m300m300m250m250m200m200m150m150m100m100m50m50m00442m(179m)262m(225m)37m(2m)35mRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
59.36% GROSS MARGIN
59.36%
Averages
1Year 59.36%
3Years 64.32%
5Years 65.55%
7Years 61.51%
10Years 0.00%
8.49% OPERATING MARGIN
8.49%
Averages
1Year 8.49%
3Years -12.34%
5Years -54.05%
7Years -78.73%
10Years 0.00%
8.03% NET MARGIN
8.03%
Averages
1Year 8.03%
3Years -13.70%
5Years -59.87%
7Years -89.14%
10Years 0.00%
15.51% ROE
15.51%
Averages
1Year 15.51%
3Years -7.35%
5Years -22.98%
7Years 45.15%
10Years 0.00%
4.41% ROA
4.41%
Averages
1Year 4.41%
3Years -4.07%
5Years -12.78%
7Years -21.73%
10Years 0.00%
4.98% ROIC
4.98%
Averages
1Year 4.98%
3Years -3.81%
5Years -13.12%
7Years -23.90%
10Years 0.00%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis TransMedics Group, Inc.
image
00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)(140m)(140m)(160m)(160m)(180m)(180m)(200m)(200m)201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 35.5 M
Depreciation & Amortization 19.8 M
Capital Expenditures -130 M
Stock-Based Compensation 33.2 M
Change in Working Capital -45 M
Others 37.6 M
Free Cash Flow -80.9 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets TransMedics Group, Inc.
image
Wall Street analysts predict an average 1-year price target for TMDX of $151 , with forecasts ranging from a low of $90 to a high of $208 .
TMDX Lowest Price Target Wall Street Target
90 USD -30.34%
TMDX Average Price Target Wall Street Target
151 USD 16.81%
TMDX Highest Price Target Wall Street Target
208 USD 61.00%
Price
Max Price Target
Min Price Target
Average Price Target
220220200200180180160160140140120120100100808060604040Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26Jul '26Jul '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 3
6. Ownership
Insider Ownership TransMedics Group, Inc.
image
Sold
0-3 MONTHS
1.51 M USD 3
3-6 MONTHS
184 K USD 1
6-9 MONTHS
2.11 M USD 3
9-12 MONTHS
19.8 M USD 6
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Is TransMedics Stock a Buy After Short-Seller Drama? Explore the exciting world of TransMedics (TMDX 0.97%) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities! fool.com - 1 week ago
2 Stocks That Have Doubled This Year and Are Still Worth Buying Positive, company-specific developments have led to shares of TransMedics Group (TMDX 1.08%) and FuboTV (FUBO 2.32%) more than doubling this year, even as the S&P 500 is barely in the green since January. Investing wisdom advises us to buy low, and some might think that after a greater than 100% return in six months, it's too late to get in on these stocks. fool.com - 2 weeks ago
10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential There's a strong case that healthcare is the most important sector in the stock market. These companies deliver innovative therapies and medical technologies that are often life-saving. fool.com - 2 weeks ago
Reasons to Retain TransMedics Stock in Your Portfolio for Now TMDX continues to witness growth on the back of its strength in OCS technology and the National OCS Program. zacks.com - 2 weeks ago
TransMedics' Turnaround: The Organ Transplant Leader Is Still A Buy TransMedics' Q1 results showcased explosive 48% revenue growth and margin recovery, reaffirming my bullish thesis on its OCS technology and logistics moat. Despite new risks like competition and logistics costs, TMDX's execution, clinical edge, and management's ambitious growth targets support long-term market dominance. Valuation remains compelling: strong EPS growth and frequent estimate beats can sustain premium multiples as it scales. seekingalpha.com - 3 weeks ago
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against TransMedics Group, Inc. (TMDX) And Encourages Shareholders to Reach Out NEW YORK CITY, NY / ACCESS Newswire / June 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of TransMedics Group, Inc. ("TransMedics" or "the Company") (NASDAQ:TMDX). Investors who purchased TransMedics securities prior to February 3, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TMDX. accessnewswire.com - 4 weeks ago
Bronstein, Gewirtz & Grossman, LLC Encourages TransMedics Group, Inc. (TMDX) Stockholders to Inquire about Securities Investigation NEW YORK CITY, NY / ACCESS Newswire / June 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of TransMedics Group, Inc. ("TransMedics" or "the Company") (NASDAQ:TMDX). Investors who purchased TransMedics securities prior to February 3, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TMDX. accessnewswire.com - 1 month ago
Mid-Cap Marvels: 3 Stocks That Crushed Sales Estimates in May In May, three stocks that released earnings stood out due to their massive sales beats. These names are mid-cap companies with market capitalizations between $2 billion and $10 billion. marketbeat.com - 1 month ago
Kuehn Law Encourages Investors of TransMedics Group, Inc. to Contact Law Firm NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of TransMedics Group, Inc. (NASDAQ: TMDX) breached their fiduciary duties to shareholders. globenewswire.com - 1 month ago
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against TransMedics Group, Inc. (TMDX) and Encourages Investors to Learn More About the Investigation NEW YORK CITY, NY / ACCESS Newswire / June 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of TransMedics Group, Inc. ("TransMedics" or "the Company") (NASDAQ:TMDX). Investors who purchased TransMedics securities prior to February 3, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TMDX. accessnewswire.com - 1 month ago
3 Medical Technology Stocks Outperforming in 2025 As the broader market stages a sharp rebound from its April lows, several sectors, industries, and stocks have quietly emerged as leaders. Among them, the medical technology industry, known for its innovation and growth potential, has stood out. marketbeat.com - 1 month ago
TransMedics Group, Inc. (TMDX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation NEW YORK CITY, NY / ACCESS Newswire / June 8, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of TransMedics Group, Inc. ("TransMedics" or "the Company") (NASDAQ:TMDX). Investors who purchased TransMedics securities prior to February 3, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TMDX. accessnewswire.com - 1 month ago
8. Profile Summary

TransMedics Group, Inc. TMDX

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 4.37 B
Dividend Yield 0.00%
Description TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
Contact 200 Minuteman Road, Andover, MA, 01810 https://www.transmedics.com
IPO Date May 2, 2019
Employees 728
Officers Mr. Anil Ranganath Senior Vice President, General Counsel & Corporate Secretary Ms. Miriam C. Provost Ph.D. Vice President of Global Regulatory Affairs Mr. Gerardo Hernandez Chief Financial Officer & Treasurer Dr. Waleed H. Hassanein M.D. Founder, President, Chief Executive Officer & Director Mr. Nicholas Corcoran Senior Vice President of Supply Chain & Operations Dr. Tamer I. Khayal M.D. Chief Commercial Officer